Sign in to view content

Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER

Arshad M. Khanani, MD, MA, FASRS

Video
Published 2018

Related

What Happens to Diabetic Retinopathy Severity Scores With Less Aggressive Treatment? A Post Hoc Analysis of the RISE and RIDE Open Label Extension Study
Roger A. Goldberg, MD, MBA
Updates from the Field
2019
Outcomes of DRCR Network Treatment Regimen Starting with Observation for Eyes With Center-involved Diabetic Macular Edema and Good Visual Acuity
Omar S. Punjabi, MD
Updates from the Field
2019
Brolucizumab for the Treatment of Visual Impairment Due to Diabetic Macular Edema: 52-Week Results From the KESTREL and KITE Studies
David M. Brown, MD
Annual Meeting Talks
2021

Category: Age-Related Macular Degeneration

See more